N4 Pharma is a pre-clinical stage specialist pharmaceutical company developing Nuvec®, a unique novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Established in 2014 and floated on the AIM stock market in May 2017.
Nuvec® is currently in the pre-clinical phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems.
Learn more
Watch our new video animation below to see Nuvec® in action:
Latest news and updates
News: N4 Pharma to support with the development of a new nanoparticle delivery system
The University of Queensland has announced that Professor Chengzhong Yu, Senior Group Leader, Australian Institute for Bioengineering and Nanotechnology (AIBN) has been awarded a $402,115 grant to develop an improved nanoparticle delivery system that enhances [...]
Video: SiRNA transfection with Nuvec® and subsequent inhibition of mRNA translation
Our new animation displays how Nuvec’s® unique spiky structure and large surface area allow it to efficiently load, protect and deliver multiple siRNA to a target cell through endocytosis. Once delivered to the cytoplasm, the [...]
Article: Could new-generation silica nanoparticles be the next big thing in siRNA delivery systems for cancer treatment?
In our latest article, we look at how Nuvec® offers an alternative to current drug delivery approaches for small interfering RNA (siRNA). Not only is Nuvec® particularly suited to chemical modification, allowing the addition of target [...]